Metastatic advanced renal cancer. Medical search. Frequent questions

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma. (survivornet.com)
Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly diagnosed renal cell cancers. (mdpi.com)
This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). (biomedcentral.com)
Pathological examination of the surgical specimens demonstrated pT3cN0Mx conventional (clear cell) renal carcinoma, Fuhrman Grade 3 with negative surgical margins. (biomedcentral.com)
Background Non-clear cell renal cell carcinoma (nccRCC) represents around 25% of RCC variants. (bmj.com)
Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. (bmj.com)
Intratumoral heterogeneity, including in clear cell renal cell carcinoma, is a potential cause of drug resistance and metastatic cancer progression. (nih.gov)
We specified the heterogeneous population marked by endoglin (also known as CD105) in a preclinical model of clear cell renal cell carcinoma progression. (nih.gov)
Highly malignant derivatives of human clear cell renal cell carcinoma OS-RC-2 cells were established as OS5Ks by serial orthotopic inoculation in our previous study. (nih.gov)
In conclusion, the renal microenvironment, rather than the hypothesized ENG + cell-centered hierarchy, maintains cellular heterogeneity in clear cell renal cell carcinoma. (nih.gov)
Primary objective: To assess the early signals for anti-tumor activity (i.e. objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma. (bcan.org)
This is a Phase I/Ib, open-label, safety, and pharmacodynamics study of pembrolizumab in combination with vorinostat in patients with advanced prostrate, renal or urothelial cell carcinoma. (bcan.org)
The Dose Finding Phase will estimate the Recommended Phase II Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. (bcan.org)
3. Prostate cell carcinoma - progressive disease, locally advanced or metastatic disease (enrolling only at IUSCC and its affiliates). (bcan.org)
Combination lenvatinib and pembrolizumab demonstrated antitumor activity in patients with metastatic renal cell carcinoma (RCC) regardless of prior treatment, according to trial results published in The Lancet Oncology . (cancertherapyadvisor.com)
Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. (pharmacytimes.com)
Endometrial carcinoma (EC) in combination with pembrolizumab for the treatment of patients with advanced EC that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy, and are not candidates for curative surgery or radiation. (pharmacytimes.com)
The approval was based on data from KEYNOTE-590 ( NCT03189719 ), a multicenter, randomized, double-blind placebo-controlled trial that enrolled 749 patients with locally advanced unresectable or metastatic esophageal or GEJ carcinoma (Siewert Type I) who were not candidates for surgical resection or definitive chemoradiation. (merck.com)
Renal cell carcinoma accounts for about 2% of all adult malignancies. (intechopen.com)
Dr. Pagliaro is interested in how molecularly targeted drugs and immune checkpoint inhibitors can be combined for the treatment of advanced renal cell carcinoma and prostate cancer. (mayo.edu)
Renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) are the two most common types of kidney cancer. (ahrq.gov)
4 While renal cell carcinoma only represents 2% of adult cancers, it is among the most lethal, with approximately 35% of patients dying within 5 years of diagnosis. (ahrq.gov)
8 However, the deaths due to renal cell carcinoma are driven by the failure of systemic treatments in metastatic (later stage) patients. (ahrq.gov)
All solid renal masses and cystic lesions with solid components are suspicious for renal cell carcinoma. (ahrq.gov)
No test is effective at screening for renal cell carcinoma, and most tumors are detected incidentally during an evaluation for unrelated or non-specific complaints. (ahrq.gov)
Treatment protocols for renal cell carcinoma are provided below, including treatment of localized and advanced disease and recommendations for patients with predominantly clear cell carcinoma and those with predominantly non-clear cell carcinoma. (medscape.com)
The therapeutic approach for renal cell carcinoma is guided by the probability of cure, which is related directly to the stage or degree of tumor dissemination. (medscape.com)
See Renal Cell Carcinoma: Recognition and Follow-up , a Critical Images slideshow, to help evaluate renal masses and determine when and what type of follow-up is necessary. (medscape.com)
Assistance with the prescription drugs and biologics used in the treatment of renal cell carcinoma. (healthwellfoundation.org)
1. You are being treated for Renal Cell Carcinoma. (healthwellfoundation.org)
A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial. (sciencedaily.com)
Renal cell carcinoma is the most common form of kidney cancer, diagnosed annually in more than 330,000 patients worldwide and causing over 140,000 deaths. (sciencedaily.com)
The multi-center trial enrolled 658 patients with clear cell renal carcinoma, which makes up over 80 percent of people with kidney cancer. (sciencedaily.com)
The patients had advanced or metastatic renal cell carcinoma whose disease had worsened following first-line therapy with drugs that target the vascular endothelial growth factor receptor (VEGFR). (sciencedaily.com)
You are scheduled to receive second-line treatment for renal cell carcinoma that is progressing and is causing symptoms. (esmo.org)
Low-dose nivolumab in advanced hepatocellular carcinoma. (nature.com)
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. (nature.com)
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma. (worldpharmanews.com)
The overall response rate and durability of response favored the combination of Opdivo and Yervoy, and the trend for PFS supports the potential of the combination in intermediate and poor-risk advanced renal cell carcinoma, the most common type of kidney cancer. (worldpharmanews.com)
Opdivo is now well established as standard of care in the treatment of second-line renal cell carcinoma," said Goodman. (worldpharmanews.com)
CheckMate -214 is a phase 3, randomized, open-label study evaluating the combination of Opdivo plus Yervoy versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma. (worldpharmanews.com)
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than 100,000 deaths worldwide each year. (worldpharmanews.com)
Cabometyx - a tyrosine kinase inhibitor which prevents cancer cell growth - is an oral tablet that has been approved in the United States to treat several diseases, including advanced renal cell carcinoma, locally advanced or metastatic differentiated thyroid cancer and hepatocellular carcinoma for patients who have previously been treated with Nexavar (sorafenib). (curetoday.com)
Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy. (pharmaceutical-technology.com)
It was also under development for the treatment of relapsed/refractory multiple myeloma, salivary gland, cancer and adenoid cystic carcinoma (ACC). (pharmaceutical-technology.com)
Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). (pharmaceutical-technology.com)
The drug's sales are growing from continued strong momentum in metastatic indications, including some types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma cancers, and a rapid uptake across recent earlier-stage launches. (zacks.com)
Laparoscopic nephrectomy: Not just for localized renal cell carcinoma? (urologytimes.com)
Intermediate-term oncologic results after laparoscopic radical nephrectomy for locally advanced renal cell carcinoma are similar to those of open nephrectomy. (urologytimes.com)
Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. (uni-luebeck.de)
Rocapuldencel-T is an autologous dendritic cell immunotherapy for patients with metastatic renal cell carcinoma about which we have written previously. (shu.edu)
Translocation carcinoma is a renal cell carcinoma (RCC) subtype that harbors a translocation involving a member of the microphthalmia transcription factor gene family. (medscape.com)
In Xp11.2 translocation-associated renal cell carcinoma (RCC), cells typically have voluminous cytoplasm, which can range from eosinophilic and granular to clear. (medscape.com)
In Xp11.2 translocation-associated renal cell carcinoma, tumor cells with abundant eosinophilic cytoplasm and high nuclear grade are often arranged in large nests with a delicate, intervening vascular stroma. (medscape.com)
Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients. (nature.com)
Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: a qualitative interview study with patients, caregivers, and physicians [abstract]. (nature.com)
Patient preferences and expectations of systemic therapy in renal cell carcinoma [abstract]. (nature.com)
Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis [abstract]. (nature.com)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. (urotoday.com)
The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. (urotoday.com)
The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma. (urotoday.com)
In the ongoing, randomised, open-label, phase 3 KEYNOTE-426 study, adults (≥18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enrolled in 129 sites (hospitals and cancer centres) across 16 countries. (urotoday.com)
Randomisation was done using an interactive voice response system or integrated web response system, and was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and geographical region. (urotoday.com)
These results continue to support the first-line treatment with pembrolizumab plus axitinib as the standard of care of advanced renal cell carcinoma. (urotoday.com)
A phase 3 study evaluating nivolumab (Opdivo) plus ipilimumab (Yervoy) as an adjuvant treatment in patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse did not meet its primary endpoint. (renalandurologynews.com)
Even with notable progress in the treatment of metastatic renal cell carcinoma, there are still limited treatment options available for patients with localized disease," said Dana Walker, MD, MSCE, vice president, development program lead, genitourinary cancers, Bristol Myers Squibb. (renalandurologynews.com)
Bristol Myers Squibb provides update on CheckMate -914 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as adjuvant treatment of localized renal cell carcinoma. (renalandurologynews.com)
Renal cell carcinoma (RCC) is the most common renal cancer. (msdmanuals.com)
They have been hailed as breakthrough treatments for advanced neoplasias, including metastatic melanoma , non- small-cell lung cancer , and advanced renal-cell carcinoma. (medscape.com)
Context While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. (lu.se)
A novel coagulation-related lncRNA predicts the prognosis and immune of clear cell renal cell carcinoma. (cdc.gov)
Correction to: ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations. (cdc.gov)
A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study. (cdc.gov)
Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy. (cdc.gov)
Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? (cdc.gov)
CT-Based Radiogenomics of P4HA3 Expression in Clear Cell Renal Cell Carcinoma. (cdc.gov)
CYBA as a Potential Biomarker for Renal Cell Carcinoma: Evidence from an Integrated Genetic Analysis. (cdc.gov)
Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma. (cdc.gov)
SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. (cdc.gov)

ErbB-1 and ErbB-2 are found in many human cancers, and their excessive signaling may be critical factors in the development and malignancy of these tumors. (wikipedia.org)
Urothelial tumors of the renal pelvis and ureters (upper urinary tract) are relatively rare. (medscape.com)
Tumors of the renal pelvis account for approximately 10% of all renal tumors and only 5% of all urothelial tumors of the urinary tract. (medscape.com)
Ureteral tumors occur about one half as often as tumors located in the renal pelvis. (medscape.com)
Unlike bladder cancer, in which 80% of tumors are noninvasive, only 40% of upper tract tumors are noninvasive. (medscape.com)
Affected patients frequently present with moderately to poorly differentiated tumors and advanced disease. (medscape.com)
KEYTRUDA is indicated under accelerated approval for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (merck.com)
KEYTRUDA is indicated under accelerated approval for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (merck.com)
Stage 4 renal cancer treatment may also include radiation therapy instead of surgery to shrink tumors and ease symptoms. (cancercenter.com)
Renal masses are a biologically heterogeneous group of tumors, ranging from benign masses, to indolent cancers that behave in a benign fashion, and finally, extremely aggressive and deadly cancers. (ahrq.gov)
1,2 The true incidence of renal masses (including benign lesions) is unknown, but benign lesions comprise approximately 20% of surgically resected tumors. (ahrq.gov)
5 The greatest increase in incidence was noted in small, clinically-localized tumors (i.e. tumors within the kidney with no evidence of local spread, lymph node involvement or distant metastases), now upwards of 40% of all kidney cancers. (ahrq.gov)
9, 10 Importantly, approximately 40% of clinically localized tumors are determined to be locally-advanced cancers (stage T3, with invasion of perinephric fat or venous structures) at pathological examination. (ahrq.gov)
11 Locally advanced cancers have a significantly worse prognosis than localized tumors. (ahrq.gov)
GETNE1509) reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that lenvatinib produced durable responses in patients with previously treated advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors. (ascopost.com)
Investigators conducted a pre-clinical trial in mice transplanted with kidney cancer from over 20 patients and showed that the HIF-2 inhibitor PT2399 controlled cancer in half of the tumors, according to a study published in the journal Nature . (eurekalert.org)
Our deep expertise and innovative clinical trial designs position us to advance the I-O/I-O, I-O/chemotherapy, I-O/targeted therapies and I-O/radiation therapies across multiple tumors and potentially deliver the next wave of therapies with a sense of urgency. (worldpharmanews.com)
The company's pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory solid tumors. (pharmaceutical-technology.com)
Although the procedure is a well-established treatment modality for organ-confined clinical stage T1-2 renal tumors that are not treatable by nephron-sparing surgery, its role in the management of higher-stage tumors, although, is not yet established. (urologytimes.com)
Indeed, practice patterns are evolving toward a laparoscopic standard of care for many renal tumors, yet there will likely always be a role for open surgery. (urologytimes.com)
The study, in which the VHIO Thoracic Tumors Group and Cancer Genomics Group have participated, together with the Dana-Farber Cancer Institute, has unmasked one of the main mechanisms of resistance to this new drug. (vhio.net)
According to the Spanish Association Against Cancer (AECC), around 20,000 cases are diagnosed each year in Spain, representing 18.4% of all tumors in men (18,000 cases) and 3.2% in women (2,000 cases). (vhio.net)
Opdivo and Opdivo-based combinations have shown survival benefits in several earlier-stage and advanced cancers, including genitourinary tumors, and we are disappointed that the final analysis of CheckMate -914 Part A did not show this same benefit for the postsurgical treatment of patients with localized RCC. (renalandurologynews.com)
RCC, an adenocarcinoma, accounts for 90 to 95% of primary malignant renal tumors. (msdmanuals.com)
Patient summary We examined the literature to determine the most effective treatments for advanced kidney cancer patients whose tumors are not of the clear cell subtype. (lu.se)
Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution. (lu.se)

As a National Cancer Institute-designated comprehensive cancer center, City of Hope's bladder cancer program is uniquely positioned to provide personalized and comprehensive treatment plans, along with access to groundbreaking clinical trials. (cityofhope.org)
Our world-class experts offer bladder cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies. (cityofhope.org)
At City of Hope, we lead the way in innovative and thoughtful surgical approaches to treating bladder cancer. (cityofhope.org)
He also studies novel drug combinations for the treatment of metastatic bladder cancer. (mayo.edu)
He has developed a safe and highly effective chemotherapy treatment for patients with bladder cancer who are unable to receive the standard cisplatin-based chemotherapy. (mayo.edu)
Cabometyx is under clinical development by Exelixis and currently in Phase II for Bladder Cancer. (pharmaceutical-technology.com)
According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. (pharmaceutical-technology.com)
Roche will be collaborating with BioNTech to develop personalized vaccines based on BioNTech's mRNA products combined with Roche's PD-L1 checkpoint inhibitor, Tecentriq (atezolizumab), which was approved for bladder cancer in May 2016. (shu.edu)
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection. (lu.se)

He also discusses the current and future role of immunotherapy in kidney cancer. (uctv.tv)
Kidney cancer is usually treated with a combination of nephrectomy (surgical removal of all or part of the kidney), radiation therapy, immunotherapy, chemotherapy and hormone therapy. (healthwellfoundation.org)
Low-dose immunotherapy in head and neck cancer: a randomized study. (nature.com)
How Does Cancer Immunotherapy Work? (clocate.com)
Vaccine strategies for cancer immunotherapy depend on the induction of dendritic cells (DC) in close proximity to T cells. (shu.edu)
Speaking with Medscape Medical News prior to the AACE meeting, oncologist Jonathan Powell, MD, PhD, associate director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, Baltimore, Maryland, said he and his colleagues have become "very much attuned to" this phenomenon, and that "the good news is that a lot of times we can inhibit the autoimmune response. (medscape.com)

Targeted therapies are drugs that attack cancer cells based on specific characteristics, such as the proteins they make. (cancercenter.com)
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute. (sciencedaily.com)
We want to make HIF-2 inhibitors available to patients and are currently carrying out clinical trials," said Dr. James Brugarolas, Director of the Kidney Cancer Program, who is leading an $11 million SPORE grant from the National Cancer Institute seeking to translate new discoveries into novel therapies for kidney cancer patients. (eurekalert.org)
The 11th InterAmerican Oncology Conference 2025 is dedicated to current status and future of anti-cancer therapies with a focus on advances in the treatment of cancer and conventional therapies for some of the common tumor types. (clocate.com)
With prostate cancer confirmed as the second most commonly occurring cancer in men globally, the need for innovative new therapies is extensive, especially for those whose cancer has progressed to the metastatic castration-resistant form," said Howard Mayer, executive vice president and head of research and development at Ipsen, in the press release. (curetoday.com)
Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. (pharmaceutical-technology.com)
The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. (pharmaceutical-technology.com)
At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. (uni-luebeck.de)
Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in combating cancer and delivering on the promise of precision oncology. (vhio.net)
Several newly approved therapies have substantially altered the treatment paradigm for multiple genitourinary cancers. (nature.com)
Identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapies [abstract]. (nature.com)
But when that's not possible they refer patients to the relevant specialists - at Johns Hopkins, both endocrinologists and rheumatologists are beginning to specialize in the autoimmune consequences of the new cancer therapies. (medscape.com)
Objective To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC. (lu.se)

Forty-five patients with prior treatments will be enrolled in three expansion cohorts: 15 anti-PD1 naive renal and urothelial patients 15 anti-PD1 resistant renal and urothelial patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition), and 15 patients with androgen-sensitive or castration-resistant prostate cancer. (bcan.org)
Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer. (curetoday.com)
The treatment combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) demonstrated significant improvements regarding survival without disease progression for patients with metastatic castration-resistant prostate cancer (mCRPC), according to preliminary results from a phase 3 trial. (curetoday.com)
Castration-resistant prostate cancer is when prostate cancer continues growing even though the amount of testosterone in the body reduces to very low levels, according to the National Cancer Institute. (curetoday.com)
Cabometryx) in combination with (Tecentriq) represents a potential new treatment modality for patients with metastatic castration-resistant prostate cancer, and we look forward to sharing the full data at a future medical meeting. (curetoday.com)
Patients with metastatic castration-resistant prostate cancer face a poor prognosis of less than two years, and many who progress on a novel hormonal therapy are seeking alternative treatment options to chemotherapy," said Dr. Vicki L. Goodman, executive vice president, product development and medical affairs and chief medical officer of Exelixis, in the press release. (curetoday.com)
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). (urotoday.com)
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. (urotoday.com)
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. (urotoday.com)
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). (snmjournals.org)
Despite recent approval of some novel drugs, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease and additional treatment options are still needed. (snmjournals.org)

Findings, which were presented at the 2023 ESMO Congress , showed that induction (given before the main treatment to shrink cancer) chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone. (curetoday.com)
https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (2023). (nature.com)
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care. (cancernetwork.com)
Journal of kidney cancer and VHL 2023 8 10 (3): 17-22. (cdc.gov)
Cancer genomics & proteomics 2023 8 20 (5): 469-475. (cdc.gov)

Prostate Cancer. (powershow.com)
Patients with advanced or metastatic prostate cancer can have either androgen-sensitive or castration-resistant disease. (bcan.org)
He has published over 150 peer-reviewed papers, 5 book chapters and over 150 abstracts in the fields of kidney transplantation, urologic laparoscopy, and urologic oncology with focus on kidney cancer and prostate cancer. (intechopen.com)
Prostate Cancer Local Staging with Magnetic Resonance Imaging. (urotoday.com)
A Repurposing Programme Evaluating Repurposing Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design. (urotoday.com)
Prostate Cancer, Race, and Health Disparity: What We Know. (urotoday.com)
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. (urotoday.com)
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. (urotoday.com)
68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study. (urotoday.com)
Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival? (urotoday.com)
Genetic and biological drivers of prostate cancer disparities in Black men. (urotoday.com)
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. (urotoday.com)
Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia. (urotoday.com)
MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease. (urotoday.com)
Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men. (urotoday.com)
We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process,' says David M. Schuster, MD, FACR. (urologytimes.com)
In the first article of this series, Nilay Gandhi, MD, explains the treatment and management of patients with advanced/metastatic prostate cancer and details the options for androgen deprivation therapy. (urologytimes.com)
It is found in most prostate cancers ( 1 ), and its overexpression correlates with traditional adverse prognostic factors ( 2 ). (snmjournals.org)
In contrast, prostate cancer is usually radiosensitive. (snmjournals.org)
Radiotherapy is a standard treatment for localized prostate cancer, for palliative management of mCRPC, and even radiopharmaceuticals targeting the surrounding bone matrix instead of the tumor itself can improve survival ( 5 ). (snmjournals.org)
Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. (medscape.com)
Prostate cancer is the second leading cause of cancer-related deaths in the United States among men and the most commonly diagnosed cancer in American males. (medscape.com)
Most prostate cancer-related deaths are due to advanced disease, which results from any combination of lymphatic, blood, or contiguous local spread. (medscape.com)
High-grade prostate cancer, particularly the percentage presence of Gleason grades 4 and 5, is associated with adverse pathologic findings and disease progression. (medscape.com)
For patient education information, see the Men's Health Center and the Cancer Center , as well as Prostate Cancer . (medscape.com)
An estimated 1 in 10 men will develop prostate cancer in their lifetime, with the likelihood increasing with age. (medscape.com)
Since the advent of prostate-specific antigen (PSA) screening, prostate cancer is being detected and treated earlier. (medscape.com)
Accumulating evidence is showing that, owing to early diagnosis and treatment, the mortality rate associated with prostate cancer has declined since the 1970s. (medscape.com)
Despite the apparent survival advantage of early diagnosis conferred by PSA screening, a 2008 US Preventive Services Task Force statement recommended against screening for prostate cancer in men aged 75 years or older. (medscape.com)
The statement also concluded that the current balance of benefits versus drawbacks of prostate cancer screening in men younger than 75 years cannot be assessed because of insufficient evidence. (medscape.com)
As a result of its genetic linkage, prostate cancer is more common in males with a strong family history of prostate cancer. (medscape.com)
In addition, prostate cancer tends to not only be more aggressive and progressive in black males, leading to advanced disease, but to also be of a higher grade at diagnosis in this population. (medscape.com)
The mortality rate associated with prostate cancer continues to increase in Europe and in countries such as Australia, Japan, and Russia. (medscape.com)
Advanced prostate cancer results from any combination of lymphatic, blood, or contiguous local spread. (medscape.com)
Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC) [abstract]. (nature.com)
Evaluation of organized prostate cancer testing. (lu.se)

The effective treatment of metastatic RCC with systemic targeted therapy gives a strong rationale for its use as adjuvant treatment in high-risk patients. (intechopen.com)
Tecentriq is an immune checkpoint inhibitor, which is a type of targeted therapy drug, and is also considered a monoclonal antibody that binds to the protein PD-L1 on the surface of certain cancer cells, preventing the cancer cells from suppressing the immune system, as noted from the National Cancer Institute. (curetoday.com)
Cabometyx is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. (pharmaceutical-technology.com)
Thanks to the discovery of molecular alterations that in turn led to the development of much more targeted therapy - as was already occurring for other tumor types, the prospects for treating lung cancer began to improve a few years ago. (vhio.net)
Treatment is with surgery for early disease and targeted therapy, an experimental protocol, or palliative therapy for advanced disease. (msdmanuals.com)

This is an important study in first-line renal cancer as these patients need new options," said Vicki Goodman, M.D., development lead, Melanoma and Genitourinary Cancers, Bristol-Myers Squibb. (worldpharmanews.com)

Has locally advanced/metastatic disease (ie, Stage IV per the American Joint Committee on Cancer). (survivornet.com)
In 2007, a 58-year-old white male with no history of tobacco use, hypertension, diabetes, or hypercholesterolemia, and no family history of coronary artery disease, was found to have a large solid right renal mass and associated tumor thrombus of the inferior vena cava and right atrium. (biomedcentral.com)
During December 2008, in a setting of stable disease, he underwent hepatic resection and enucleation of the left renal mass. (biomedcentral.com)
Early radiological assessment after surgery showed no residual hepatic or renal disease, but possible involvement of the mesenteric lymph nodes. (biomedcentral.com)
Lenvatinib plus pembrolizumab might therefore be a future potential standard-of-care treatment for patients with metastatic clear cell RCC after disease progression with ICI therapy. (cancertherapyadvisor.com)
Our research with KEYTRUDA has contributed to recent advances in the treatment of gastric cancer, and we are continuing to advance studies to help more patients with this disease. (merck.com)
The survival rate for metastatic kidney cancer depends on a variety of factors, including the patient's age, overall health and the extent of the disease. (cancercenter.com)
Patients must have no evidence of metastatic disease based on screening computed tomography or magnetic resonance imaging. (cityofhope.org)
Dr. Kapoor is current Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Program Director of the McMaster University Urology Residency Program, and Co-Chair of the NCIC Kidney Cancer Disease Group. (intechopen.com)
Dr. Pagliaro's research contributes to improved standard treatment of penile cancer with spread to lymph nodes, and patients are now frequently cured of the disease. (mayo.edu)
Preoperative patient and tumor (imaging) characteristics are used to stratify the risk of benign versus malignant disease, and indolent versus aggressive cancers. (ahrq.gov)
Dr. Won Kim reviews the epidemiology of kidney cancer (including established risk factors), the biology and pathophysiology of kidney cancer, treatment options for localized disease, and the role of systemic therapy in the treatment of advanced, metastatic disease. (uctv.tv)
There are few, if any, more difficult clinical challenges than pancreatic cancer, a disease that continues to confound the oncology community's quest for cure. (ascopost.com)
Approximately 20-33% of all cancer patients are treated with acid reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastro esophageal reflux disease symptoms. (researchsquare.com)
About 30 percent of people who are diagnosed with RCC develop advanced (metastatic) disease, in which the cancer spreads to other parts of the body- most often the bones or lungs. (healthwellfoundation.org)
however, up to 30% of patients still relapse and die from metastatic disease. (curetoday.com)
Drugs that target VEGFR are standard therapy for advanced disease and can be very effective initially, but in many cases tumor cells find ways to escape the drugs' attack. (sciencedaily.com)
One survey reported that about one half of British cancer specialists stopped chemotherapy after six months if patients with metastatic disease responded well, whereas 30 percent would stop therapy after three months, and 20 percent would continue therapy indefinitely. (aafp.org)
Patients were required to have adequate bone marrow and renal function and could not have had previous chemotherapy for metastatic disease. (aafp.org)
You are due to undergo surgery for metastatic disease. (esmo.org)
You are scheduled to receive first-line treatment for intermediate- or high-risk metastatic disease. (esmo.org)
Preliminary findings from the trial established that the use of Cabometyx combined with Tecentriq has demonstrated a significant improvement in progression-free survival (PFS), defined as the period during and after treatment of cancer when the disease does not worsen, during the primary analysis. (curetoday.com)
The earlier definition of advanced disease (bone metastasis and soft-tissue involvement) has also been improved. (medscape.com)
nonetheless, advanced disease is comparably less common, because more early stage cancer is being discovered. (medscape.com)
as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
Although pulmonary carcinoids show relatively good prognosis in comparison to carcinomas, metastatic disease and relapse do occur. (who.int)

We have seen few advances over the last three decades that have improved historically poor survival outcomes for patients with esophageal cancer," said Professor Antoine Adenis, Department of Medical Oncology, Montpellier Cancer Institute, France. (merck.com)
He is certified by the American Society of Transplant Surgeons, having obtained post-graduate training from the Cleveland Clinic Foundation in Renal Transplantation and GU Oncology. (intechopen.com)
In a single-institution study reported in JAMA Oncology, Reyngold et al found that definitive hypofractionated ablative radiation therapy following induction chemotherapy was associated with prolonged locoregional control and favorable survival in patients with inoperable locally advanced. (ascopost.com)
Our vision for the future of cancer care is focused on researching and developing transformational Immuno-Oncology (I-O) medicines for hard-to-treat cancers that could potentially improve outcomes for these patients. (worldpharmanews.com)
Collaboration between investigators from the Vall d'Hebron Institute of Oncology (VHIO) and the Dana-Farber Cancer Institute (Boston, USA), among others, has led to the identification of a mechanism of resistance to a new drug under clinical investigation for advanced lung cancer. (vhio.net)

HIF-2 also appears significant in other types of cancer, including deadly brain cancers called glioblastomas and non-small cell lung cancer, the most common type of lung malignancy. (eurekalert.org)
AZN - Free Report ) Tagrisso (osimertinib) for patients with late-stage non-small cell lung cancer (NSCLC). (zacks.com)
This discovery, published today in Nature Medicine , deriving from research into circulating DNA in plasma (cfDNA) and tumor biopsies from patients with advanced non-microcytic lung cancer in a clinical trial, has described resistance mutations to this new therapy inhibiting mutation of the EGFR protein. (vhio.net)
The mutation of EGFR, a tyrosine kinase receptor present in approximately 10% of patients with advanced non-microcytic lung cancer, which leads to protein activation, is one example. (vhio.net)
That discovery gave rise to the very first agents to inhibit this protein, which were successfully applied to this subtype of lung cancer. (vhio.net)
Lung cancer is the most common cancer worldwide, with 1,400,000 new cases diagnosed every year. (vhio.net)
Background: In some settings, lung cancer incidence appears higher among disadvantaged groups. (who.int)
We analyzed the harmonized database of the Lung Cancer Cohort Consortium (LC3) to assess the relationship between socioeconomic status and lung cancer incidence across different world regions. (who.int)
Separately for never or currently/formerly smoking participants, we estimated the association between educational level (as a proxy for socioeconomic status, modeled in 4 categories) and incident lung cancer using Cox proportional hazards models. (who.int)

Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer types. (nature.com)
Newer immunotherapeutic agents, including vaccines and so called 'checkpoint inhibitors,' have been developed to specifically target the body's immune system and enable it to recognize and attack cancer cells more specifically. (cochrane.org)
AUSTIN, Texas - Cancer patients receiving treatment with recently approved immune checkpoint inhibitors are increasingly developing endocrine disorders that are mostly mild, but in some cases can be serious, new research suggests. (medscape.com)
And previous research suggests that the patients who develop adverse events from immune checkpoint inhibitors are the ones whose cancers are most likely to respond to them. (medscape.com)

Translocation-associated renal cell carcinomas (RCCs) arise from the proximal tubule epithelium, similar to conventional clear cell and papillary RCCs. (medscape.com)
Xp11.2 translocation-associated renal cell carcinomas are generally cortical or subcapsular, well-circumscribed lesions with yellow-tan, variegated cut surfaces. (medscape.com)
Xp11.2 translocation-associated renal cell carcinomas (RCCs) may have well-developed papillae, mimicking papillary RCCs. (medscape.com)
The nests of tumor cells in Xp11.2 translocation-associated renal cell carcinomas may become centrally discohesive, giving rise to a pseudoalveolar growth pattern. (medscape.com)

KEYTRUDA is indicated under accelerated approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma. (merck.com)
The European Commission's approval of KEYTRUDA plus chemotherapy for the treatment of certain patients with esophageal and HER2-negative GEJ cancer provides a new option in the first-line setting that has shown significant improvements in progression-free and overall survival. (merck.com)
Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer. (curetoday.com)
Platinum-based chemotherapy, given before chemoradiation, improved outcomes for patients with advanced cervical cancer. (curetoday.com)
Patients with locally advanced cervical cancer saw an improvement in survival when they added platinum-based chemotherapy before chemoradiation, compared to those who had chemoradiation alone, according to findings from the phase 3 INTERLACE clinical trial. (curetoday.com)
Induction chemotherapy with weekly paclitaxel and carboplatin delivered immediately before chemoradiation should be considered the new standard in locally advanced cervical cancer and is feasible across diverse health care settings," lead study author Mary McCormack, of University College London in the United Kingdom, said in a presentation of the data. (curetoday.com)
Patients needed to be fit for chemotherapy and radical radiotherapy and have adequate renal, liver and bone marrow function. (curetoday.com)
Fluorouracil-based chemotherapy for colorectal cancer usually is not limited by cumulative toxic effects and can be continued for long periods. (aafp.org)
Maughan and colleagues compared intermittent chemotherapy with continuous treatment in patients whose advanced colorectal cancer responded or stabilized after an initial 12-week course of chemotherapy. (aafp.org)
TOPAZ-1 was a clinical trial studying the addition of durvalumab, the PD-1 inhibitor, to the standard chemotherapy regimen of gemcitabine and cisplatin in the treatment of unresectable cholangiocarcinoma or biliary [tract cancer]. (cancernetwork.com)

Targeted drugs such as thyrosine kinase inhibitors and cyclin-dependent kinase inhibitors are widely used in cancer patients. (researchsquare.com)
The clinical efficacy of the combination of a CDK 4/6 inhibitor with aromatase inhibitors or fulvestrant has been acknowledged as the invention therapy in the first-second line treatment of human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive premenopausal and postmenopausal women with advanced breast cancer [10-13]. (researchsquare.com)
DALLAS - September 05, 2016 -A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found. (eurekalert.org)
Part of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors. (eurekalert.org)
Unlike existing VEGF inhibitors, the HIF-2 inhibitor blocks VEGF only in the cancer and therefore does not cause cardiac toxicity or hypertension," Dr. Brugarolas explained. (eurekalert.org)

Their diagnostic and therapeutic management has been improved by advances in imaging and endo-urology. (scirp.org)

Differentiated thyroid cancer (DTC) as a single agent to treat patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. (pharmacytimes.com)

This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. (mayo.edu)
It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer. (mayo.edu)

However, most data about use of nivolumab and ipilimumab (nivo-ipi) in kidney cancer comes from one trial in clear cell RCC (ccRCC). (bmj.com)
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carnioma: results from the phase 3b/4 CheckMate 920 trial. (bmj.com)
The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi). (onclive.com)

In the current study, we aimed to investigate the effects of concurrent PPIs on palbociclib and ribociclib efficacy in terms of progression free survival in metastatic breast cancer (mBC) patients. (researchsquare.com)
Sellas reversed merged into Galena , a peptide vaccine company whose lead product, NeuVax, for breast cancer failed. (shu.edu)
Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer. (cdc.gov)

The decision was made in consultation with the FDA following the April 29 Oncologic Drugs Advisory Committee evaluation of this third-line gastric cancer indication for KEYTRUDA as a monotherapy because it failed to meet its post-marketing requirement of demonstrating an overall survival benefit in a Phase 3 study. (merck.com)
Stage 4 renal cancer may be treatable, but it has a low survival rate. (cancercenter.com)
According to the American Cancer Society , using the Surveillance, Epidemiology, and End Results (SEER) database, the five-year relative survival rate for distant kidney or renal pelvic cancer patients is 15 percent. (cancercenter.com)
The advent of effective combination chemotherapies has changed the treatment landscape for metastatic pancreatic cancer, extending median survival and leading to durable responses in a subset of patients. (ascopost.com)
Moreover, the early results show a "strong trend indicating that survival may be improved in patients receiving cabozantinib compared to standard therapy," said Toni K. Choueiri, MD, clinical director of the Genitourinary Cancer Treatment Center at Dana-Farber Cancer Institute, the first author of the report. (sciencedaily.com)
The main end point is progression-free survival -- how long the cancer is held in check before it starts growing again. (sciencedaily.com)
Patients with mCRPC also tend to have a poor prognosis, in which survival is estimated to be one to two years, as reported in the journal Clinical Genitourinary Cancer . (curetoday.com)
Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers. (onclive.com)

Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. (urotoday.com)
Consequently, over the past 5 years, numerous studies have been undertaken to identify which end points and values are most meaningful to patients with genitourinary cancers when considering a potential therapy. (nature.com)

Dec. 22, 2022 A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. (sciencedaily.com)
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO. (cancernetwork.com)

By inhibiting these receptors' function, lenvatinib has the potential to inhibit pathogenic angiogenesis, tumor growth, and cancer progression. (pharmacytimes.com)
Molecular paThwayS criTical for cancer developMenT and progreSSion, ThuS enhancing The evidence baSe direcTly relevanT To STudieS of cancer cauSaTion and prevenTion. (who.int)

They recruited 354 patients with inoperable or metastatic colorectal cancer from 42 British cancer centers. (aafp.org)
editor's note: Patients with advanced colorectal cancer require significant support from family physicians. (aafp.org)
It is indicated for the reduction of cytotoxicity when used in combination with 5-fluorouracil in the treatment of colorectal cancer and for the treatment of megaloblastic anemia due to folic acid deficiency when folic acid cannot be replaced orally. (janusinfo.se)
The following regimens have been used in adults and elderly in the treatment of advanced or metastatic colorectal cancer and are given as examples. (janusinfo.se)

Merck's clinical program in gastric cancer includes the first-line Phase 3 studies KEYNOTE-811, KEYNOTE-859 and LEAP-015, as well as KEYNOTE-585 in the neoadjuvant and adjuvant treatment setting. (merck.com)
Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 3 study on the benefits of a combination therapy to treat patients with untreated locally advanced or metastatic urothelial cancer. (cityofhope.org)
Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 2 study on the benefits of atezolizumab, with or without eribulin mesylate, in treating patients with urothelial cancer that has come back, or spread to nearby tissues and lymph nodes, or other places in the body. (cityofhope.org)
Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. (cancernetwork.com)
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. (cancernetwork.com)

The retrospective study, presented by Monish Aron, MD, a clinical fellow in advanced laparoscopic urology at the Cleveland Clinic, represents one of the largest series to date specifically evaluating laparoscopic nephrectomy for higher-stage renal masses. (urologytimes.com)

[ 1 ] However, the incidence may be increasing: a population-based study in Norway reported an incidence of 4.7 per 100,000, representing 13% of all urothelial cancers from 2014-2018. (medscape.com)

Stage 4 kidney cancer life expectancy is measured as the percentage of people who are still alive five years after a diagnosis, compared to people who don't have that cancer type. (cancercenter.com)
That means compared to similar-aged people without kidney cancer, 15 percent of patients diagnosed with stage 4 kidney cancer are alive five years or more after their diagnosis. (cancercenter.com)
Kidney cancer is rarely curable once it has spread to other organs at the time of diagnosis. (cochrane.org)
Nearly 400,000 Americans are now living with a diagnosis of kidney cancer and more than 60,000 people are expected to be diagnosed with kidney cancer this year, according to the National Cancer Institute. (eurekalert.org)

This type of renal failure is called post-renal, because its etiology is downstream of the kidneys. (scirp.org)

Patients with interferon-α monotherapy probably have a shorter time to worsening of cancer. (cochrane.org)

An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). (ascopost.com)

Diffuse bone marrow involvement was a risk factor for higher grade myelosuppression but could be identified by PSMA imaging in advance. (snmjournals.org)

Phytoestrogens: Epidemiology and a possible role in cancer protection. (cdc.gov)

Prior to the use of the new targeted agents, drugs that boosted the immune response against the cancer in a non-specific way (immunotherapies) were the most widely used treatment form for people with kidney cancer that had spread to other organs. (cochrane.org)
Our differentiated clinical development program is studying broad patient populations across more than 50 types of cancers with 14 clinical-stage molecules designed to target different immune system pathways. (worldpharmanews.com)
The rationale of this approach is to bypass mechanisms by which cancer cells dampen the anti-tumor immune response, including down-regulation of MHC Class I molecules. (shu.edu)
If the cancer antigens are presented on licensed dendritic cells, logically, the immune system would be appropriately stimulated to attack the cancer. (shu.edu)
1990. Biomarkers of organ damage or dysfunction for the renal, hepatobiliary, and immune systems. (cdc.gov)

The hepatic and renal masses were confirmed to be metastases. (biomedcentral.com)
1, 19-21 In addition, all current standard imaging modalities (CT, magnetic resonance imaging (MRI) and ultrasound) are able to provide insight into whether renal masses are localized or locally advanced, thus suggesting pathologic aggressiveness. (ahrq.gov)

About half of people with kidney cancers may have no signs or symptoms. (cancercenter.com)
6%) that comprise the remainder of kidney cancers. (ahrq.gov)

Anatomy5

Organisms4

Diseases36

Chemicals and Drugs43

Analytical, Diagnostic and Therapeutic Techniques and Equipment39

Psychiatry and Psychology1

Phenomena and Processes30

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena1

Information Science4

Named Groups1

Health Care16

Geographicals1

Carcinoma82

Tumors26

Bladder cancer9

ImmunoTherapy6

Therapies13

Castration-resistant prostate cancer11

20235

Prostate36

Targeted Therapy5

Melanoma1

Disease27

Oncology5

LUNG CANCER9

Checkpoint inhibitors4

Carcinomas4

Chemotherapy10

Inhibitors5

Therapeutic1

Recurrent1

Sunitinib2

Nivolumab3

Breast Cancer3

Survival8

Genitourinary2

20222

Progression2

Colorectal Cancer4

Phase5

Nephrectomy1

Urothelial cancers1

Diagnosis4

Etiology1

Monotherapy1

Abstract1

Bone marrow1

Epidemiology1

Immune5

Masses2

Kidney cancers2